ETFIQData as of Nov 19, 2026. · etfiq.com/funds/ozem

OZEM Fact Sheet: Roundhill GLP-1 & Weight Loss ETF

Share
$28.76
close, Nov 20, 2026

Over the year to Nov 19, 2026, OZEM returned −8.8% in total and charged 0.59% a year.

1-year total return
−9.2%
to Nov 20, 2026
Expense ratio
0.59%
a year
Net assets
$53m
on Nov 20, 2026
Net flow, last 5 trading days
$0
daily basis to Nov 19, 2026

Growth of $10,000, 1 year

OZEM $9,123 −8.8% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

Returns

WindowTotal return
1 month−4.1%
3 months−14.9%
Year to date−15.8%
1 year−9.2%
Since launch+15.0%

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HoldingWeight
Eli Lilly & Co20.55%
Novo Nordisk A/S10.70%
Chugai Pharmaceutical Co Ltd7.38%
Hanmi Pharm Co Ltd7.30%
Pfizer Inc5.85%
CSPC Pharmaceutical Group Ltd4.88%
Kailera Therapeutics Inc4.40%
Jiangsu Hengrui Pharmaceuticals Co Ltd3.93%
Hansoh Pharmaceutical Group Co Ltd3.66%
Viking Therapeutics Inc3.63%

OZEM top ten by weight, 72.3% of the fund, of its 21 equity positions, from the holdings published by its issuer for Nov 20, 2026.

Facts

Holds 21 stocks in healthcare innovation and GLP-1, 31% of its weight in S&P 500 companies · First traded May 21, 2024 · Benchmark Its own holdings, as of Nov 20, 2026; its prospectus names no index it tracks

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, OZEM Fact Sheet: Roundhill GLP-1 & Weight Loss ETF. Data as of Nov 19, 2026. https://etfiq.com/funds/ozem/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/ozem.